Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.

[1]  J. Jones,et al.  Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Lilenbaum,et al.  Phase II trial of weekly docetaxel (D) in second-line non-small cell lung cancer (NSCLC) , 2000 .

[3]  J. Zalcberg,et al.  A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Manola,et al.  Docetaxel administered on a weekly basis for metastatic breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Pavlidis,et al.  Docetaxel and Gemcitabine in Anthracycline-Resistant Advanced Breast Cancer: A Hellenic Cooperative Oncology Group Phase II Study , 2000, Cancer investigation.

[6]  Jeffrey W. Clark,et al.  A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors , 2000, Cancer.

[7]  K. Friedrichs,et al.  Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Richel,et al.  Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy , 1999 .

[9]  K. Possinger,et al.  Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. , 1999, Anti-cancer drugs.

[10]  S. Agelaki,et al.  Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Jones,et al.  Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Kubista,et al.  Second- and third-line treament of metastatic breast cancer with gemcitabine , 1998 .

[13]  M. Blackstein,et al.  Phase II study of gemcltablne in patients with metastatic breast cancer , 1997 .

[14]  P. Ravdin.  Treatment of patients resistant to anthracycline therapy , 1996, Anti-cancer drugs.

[15]  M. Trudeau.  First‐line treatment of metastatic breast cancer , 1996, Anti-cancer drugs.

[16]  P. Fumoleau,et al.  A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. , 1996, British Journal of Cancer.

[17]  E. Eisenhauer,et al.  Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Narabayashi,et al.  A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. , 1996, British Journal of Cancer.

[19]  K. Possinger.  Gemcitabine in advanced breast cancer , 1995, Anti-cancer drugs.

[20]  A. Harris,et al.  Advanced breast cancer: a phase II trial with gemcitabine. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. van Glabbeke,et al.  Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Piccart,et al.  A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  C. Spurr,et al.  Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. , 1991, The New England journal of medicine.

[24]  S. Mineishi,et al.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. Hryniuk,et al.  The calculation of received dose intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.

[27]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .